Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MSB Mesabi

Market Closed 06-18 16:00:00 EDT

24.78

+0.06

+0.24%

盘后24.78

+0.000.00%

16:10 EDT

High25.31	Low24.67	Vol40.07K
Open24.80	D1 Closing24.72	Amplitude2.58%
Mkt Cap325.11M	Tradable Cap324.86M	Total Shares13.12M
T/O999.04K	T/O Rate0.31%	Tradable Shares13.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MSB","market":"US","secType":"STK","nameCN":"Mesabi","latestPrice":24.78,"timestamp":1781812800000,"preClose":24.72,"halted":0,"volume":40065,"hourTrading":{"tag":"盘后","latestPrice":24.78,"preClose":24.78,"latestTime":"16:10 EDT","volume":19,"amount":470.82,"timestamp":1781813404900,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0024271844660195096,"floatShares":13109915,"shares":13120010,"eps":0.863187,"marketStatus":"Market Closed","change":0.06,"latestTime":"06-18 16:00:00 EDT","open":24.8,"high":25.3078,"low":24.67,"amount":999038,"amplitude":0.025801,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.863187,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":24.72,"dividendRate":0.038741,"preHourTrading":{"tag":"盘前","latestPrice":25.7292,"preClose":24.72,"latestTime":"08:28 EDT","volume":5,"amount":128.646,"timestamp":1781785726623,"change":1.0092,"changeRate":0.040825,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":24.78,"preClose":24.78,"latestTime":"16:10 EDT","volume":19,"amount":470.82,"timestamp":1781813404900,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9328288718659242,"impliedVol":0.6889,"impliedVolPercentile":0.8446},"requestUrl":"/m/hq/s/MSB/wiki","defaultTab":"wiki","newsList":[{"id":"2645965180","title":"Mesoblast (ASX:MSB) Is Up 9.2% After Ryoncil’s Near-US$100m Debut And Revascor FDA Progress – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2645965180","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645965180?lang=en_us&edition=fundamental","pubTime":"2026-06-21 00:29","pubTimestamp":1781972983,"startTime":"0","endTime":"0","summary":"Earlier this week, Mesoblast reported that Ryoncil’s first-year US launch revenue approached about US$100 million, alongside continued FDA engagement on an accelerated-approval pathway and Biologics License Application for heart failure therapy Revascor.\nThis combination of early commercial traction for Ryoncil and active regulatory dialogue on Revascor has sharpened investor focus on Mesoblast’s broader cell therapy pipeline and execution risks.\nWe’ll now examine how Ryoncil’s early US...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-92-after-ryoncils-near-us100m-debut-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-92-after-ryoncils-near-us100m-debut-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","LABU","BK4588","BK4006","MSB.AU","MSB","PRGS","LU2065732104.USD","BK7067","BK4585","BK7508","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643218325","title":"Mesabi Trust Q1 FY27 net income drops 70.05% to $1.09 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2643218325","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643218325?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:17","pubTimestamp":1781295446,"startTime":"0","endTime":"0","summary":"Mesabi Trust net income fell to USD 1.09 million, down from USD 3.63 million a year earlier; net income per unit slid to USD 0.08 from USD 0.28.Total revenues dropped to USD 2.25 million from USD 4.73 million, as royalty income sank to USD 2.08 million from USD 4.35 million.Bonus royalties were absent versus USD 1.78 million a year earlier; base overriding royalties eased to USD 1.89 million from USD 2.43 million.Distributions declared per unit declined to USD 0.24 from USD 0.56; expenses edged up to USD 1.16 million from USD 1.1 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesabi Trust published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system ope","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL1SZR2S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640998815","title":"Press Release: Mesabi Metallics Monetizes Portion of Royalty Interest for $265 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2640998815","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640998815?lang=en_us&edition=fundamental","pubTime":"2026-06-02 07:32","pubTimestamp":1780356720,"startTime":"0","endTime":"0","summary":"The $2.5 billion world-scale, low-cost DR-grade iron ore mine positions U.S. steel industry to break free from foreign imports from Brazil and other countries. The transaction further validates the exceptional quality, scale and long-term strategic importance of Mesabi Metallics' world-class Direct Reduction  grade iron ore mine, beneficiation plant and pellet plant in Minnesota, which is expected to commence production in the third quarter of 2026.\"TMCR's investment is a powerful third-party validation of the quality and strategic importance of Mesabi,\" said Artem Matyushok, Board Member of Mesabi Metallics. \"As the United States works to rebuild domestic industrial capacity and secure critical supply","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4168","MSB","BK4006","TMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640671409","title":"The Metals Royalty Company Inc. Closes Mesabi Royalty Acquisition, Exercises Option to Acquire an Additional 1% Royalty Interest and Appoints Michael Hess as Non-Executive Co-Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2640671409","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640671409?lang=en_us&edition=fundamental","pubTime":"2026-06-02 05:30","pubTimestamp":1780349408,"startTime":"0","endTime":"0","summary":"London, UK, June 1st, 2026, FinanceWire 1% Royalty Acquisition on One of the United States’ Only Large-Scale Sources of Merchant DR-Grade Iro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/the-metals-royalty-company-inc-closes-mesabi-royalty-acquisition-exercises-option-to-acquire-an-additional-1-royalty-interest-and-appoints-michael-hess-as-non-executive-co-chairman?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/the-metals-royalty-company-inc-closes-mesabi-royalty-acquisition-exercises-option-to-acquire-an-additional-1-royalty-interest-and-appoints-michael-hess-as-non-executive-co-chairman?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HES","IE00B7SZLL34.SGD","LU1169589451.USD","IE00B19Z3B42.SGD","BK4585","PICK","BK4006","LU0456854461.SGD","MSB","LU0788109394.HKD","LU0300736062.USD","BK4213","LU0266512127.USD","LU0122376428.USD","IE00B19Z3581.USD","LU0300736492.USD","BK4588","LU1169590202.USD","BK4535","IE0002270589.USD","LU0368265418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640626979","title":"The Metals Royalty Company Acquires Mesabi Royalty; Names Michael Hess as Non-Executive Co-Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2640626979","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640626979?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:42","pubTimestamp":1780346579,"startTime":"0","endTime":"0","summary":"The Metals Royalty Company  said late Monday it closed the acquisition of a 1.0% index-priced gross overriding production royalty with a revenue floor in the Mesabi Metallics iron ore project located in Nashwauk, Minnesota.The acquisition of the initial royalty was funded concurrently with proceeds from an upsized $80.1 million private placement at $13.00 per share, and a net $43 million draw under its senior secured acquisition credit facility entered into on June 1, the company said.An additional $7 million delayed draw will be accessible when it completes the acquisition of the additional 1.0% royalty, the company added.The company said it has exercised the option to buy an additional 1.0% royalty on the same terms as the initial royalty, provided the closing conditions including raising the necessary funding, are satisfied before July 31.Mesabi Metallics is targeting commissioning of operations in the second half of 2026, the company said.Metals Royalty added that it has appointed ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU1169589451.USD","TMCR","PICK","IE00B19Z3B42.SGD","BK4168","IE00B19Z3581.USD","BK4213","MSB","LU0456854461.SGD","LU0122376428.USD","LU0266512127.USD","HES","IE0002270589.USD","LU0788109394.HKD","LU1169590202.USD","LU0300736062.USD","LU0368265418.SGD","BK4535","IE00B7SZLL34.SGD","BK4588","BK4006","LU0300736492.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633972051","title":"Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L","url":"https://stock-news.laohu8.com/highlight/detail?id=2633972051","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633972051?lang=en_us&edition=fundamental","pubTime":"2026-05-07 11:57","pubTimestamp":1778126267,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) has reached full patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain, a key step toward confirmatory data supporting a potential US regulatory filing.\nSee our latest analysis for Mesoblast.\nDespite the latest clinical milestone, Mesoblast’s 1 day share price return of a 4.13% decline and 7 day share price return of a 5.86% decline show some cooling momentum. However, the 3 year total shareholder return of 102.23% reflects a strong...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7067","BK4006","MSB","BK7501","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633625909","title":"Mesabi Trust Reports Higher Shipments But No Bonus Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2633625909","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633625909?lang=en_us&edition=fundamental","pubTime":"2026-05-05 06:37","pubTimestamp":1777934254,"startTime":"0","endTime":"0","summary":"Mesabi Shs ( ($MSB) ) just unveiled an update. Mesabi Trust reported that, according to a quarterly royalty report from Cleveland-Cliffs, it receiv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesabi-trust-reports-higher-shipments-but-no-bonus-royalties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesabi-trust-reports-higher-shipments-but-no-bonus-royalties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4006","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632227266","title":"Is Completing Phase 3 Enrollment For Rexlemestrocel-L Reshaping The Investment Case For Mesoblast (ASX:MSB)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632227266","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632227266?lang=en_us&edition=fundamental","pubTime":"2026-05-02 11:34","pubTimestamp":1777692888,"startTime":"0","endTime":"0","summary":"In late April 2026, Mesoblast Limited reported it had completed patient recruitment for its pivotal 300-patient Phase 3 trial of rexlemestrocel-L in chronic low back pain due to degenerative disc disease, a placebo-controlled study designed around a 12-month pain reduction endpoint and supported by the therapy’s RMAT designation.\nThis milestone moves rexlemestrocel-L closer to potential FDA submission for a condition affecting over 7 million Americans and heavily tied to opioid use,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-completing-phase-3-enrollment-for-rexlemestrocel-l-reshap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-completing-phase-3-enrollment-for-rexlemestrocel-l-reshap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","BK7501","BK7067","BK4006","MSB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631555111","title":"Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2631555111","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631555111?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:53","pubTimestamp":1777423980,"startTime":"0","endTime":"0","summary":"NEW YORK, April  28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3283366/0/en/Mesoblast-Achieves-Patient-Recruitment-Target-in-Pivotal-Phase-3-Trial-for-Chronic-Low-Back-Pain.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","BK4150","BK4139","BK4006","BK4551","BK4588","BK4170","BK4161","MESO","MSB","MSC","DDD","BK4546","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629750895","title":"Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2629750895","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629750895?lang=en_us&edition=fundamental","pubTime":"2026-04-24 10:19","pubTimestamp":1776997156,"startTime":"0","endTime":"0","summary":"Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","BK4006","BK7501","BK7067","MSB","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629078725","title":"Mesabi Trust publishes fiscal 2026 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629078725","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629078725?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:41","pubTimestamp":1776890470,"startTime":"0","endTime":"0","summary":"Mesabi Trust filed its annual report for fiscal year ended Jan. 31, 2026, highlighting weaker royalty-driven performance tied to lower pellet shipments and pricing at Northshore.Pellet production and shipments from Mesabi Trust lands fell to 3,493,854 tons from 3,862,061 tons.Trust reported reduced bonus royalty generation late in year as limited third-party pellet sales were priced below 2026 adjusted threshold price of USD 71.7 per ton.Mesabi Trust maintained a cash reserve to manage volatile royalties, with unallocated reserve declining to USD 20.4 million from USD 23.3 million.Arbitration against Northshore and Cleveland-Cliffs remained active, targeting damages tied to 2022–2023 idling and alleged underpayment on intercompany shipments since 2023.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shou","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL47BGhb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4588","MSB","BK4585","CLF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628762489","title":"Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2628762489","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628762489?lang=en_us&edition=fundamental","pubTime":"2026-04-19 21:04","pubTimestamp":1776603864,"startTime":"0","endTime":"0","summary":"On 8 April 2026, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel‑L‑rknd) in 76 children with Duchenne muscular dystrophy, using time‑to‑stand at nine months as the primary endpoint.\nThis marks an expansion of Ryoncil’s use beyond steroid‑refractory acute graft‑versus‑host disease into another rare pediatric indication, leveraging its existing FDA‑approved manufacturing platform and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-61-after-fda-clears-registrational-dm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-61-after-fda-clears-registrational-dm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK7501","MSB","BK7067","BK4006","BK4588","MSB.AU","BK7508","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628109572","title":"Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2628109572","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628109572?lang=en_us&edition=fundamental","pubTime":"2026-04-16 22:08","pubTimestamp":1776348536,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) recently secured an exclusive worldwide license to a patented chimeric antigen receptor technology from Mayo Clinic, with the goal of refining the targeting and immune effects of its mesenchymal stromal cell therapies.\nSee our latest analysis for Mesoblast.\nAt a share price of A$2.24, Mesoblast has seen a 10.89% 1 month share price return and a 10.34% 7 day share price return. Over 90 days, the share price return is a 15.15% decline, while the 3 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","BK7508","CAR","BK4230","BK4006","BK7067","MSB.AU","BK7501","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627550421","title":"Press Release: Mesabi Trust Press Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2627550421","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627550421?lang=en_us&edition=fundamental","pubTime":"2026-04-15 04:05","pubTimestamp":1776197100,"startTime":"0","endTime":"0","summary":"The Trustees of Mesabi Trust  declared a distribution of twenty-four cents  per Unit of Beneficial Interest payable on May 20, 2026 to Mesabi Trust Unitholders of record at the close of business on April 30, 2026. This compares to a fifty-six cents  per Unit distribution declared for the same period last year.This press release contains certain forward-looking statements with respect to Northshore operations and Cliffs during 2026 and other matters, which statements are intended to be made under the safe harbor protections of the Private Securities Litigation Reform Act of 1995, as amended. Actual production, prices, price adjustments, sales, shipments and deemed shipments of iron ore pellets, as w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626889120","title":"Did FDA-Cleared Duchenne Trial for Ryoncil Just Shift Mesoblast's (ASX:MSB) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626889120","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626889120?lang=en_us&edition=fundamental","pubTime":"2026-04-12 04:28","pubTimestamp":1775939339,"startTime":"0","endTime":"0","summary":"Earlier this week, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel-L-rknd) in 76 children with Duchenne muscular dystrophy, using time-to-stand at nine months as the primary approval endpoint.\nThis move extends the use of the first FDA-approved mesenchymal stromal cell therapy beyond steroid‑refractory pediatric graft-versus-host disease and leverages a partnership with Parent Project...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/did-fda-cleared-duchenne-trial-for-ryoncil-just-shift-mesobl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/did-fda-cleared-duchenne-trial-for-ryoncil-just-shift-mesobl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK7508","LABU","BK7067","BK4006","MSB","BK7501","BK4585","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626110779","title":"Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2626110779","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626110779?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:09","pubTimestamp":1775851740,"startTime":"0","endTime":"0","summary":"Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children are living with DMD in the U.S. NEW YORK, April  10, 202","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/10/3272039/0/en/Mesoblast-Receives-IND-Clearance-From-FDA-to-Directly-Proceed-to-Registrational-Trial-for-Approval-of-Ryoncil-in-Duchenne-Muscular-Dystrophy-CORRECTION.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB","BK4585","BK4150","IND","LABU","BK4139","MESO","MSC","BK4006","BK4588","BK4575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625947672","title":"Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2625947672","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625947672?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:07","pubTimestamp":1775653620,"startTime":"0","endTime":"0","summary":"Mesoblast outlines commercial strategy to double net revenues as Ryoncil approaches US$100M net revenue milestone since launch last year  Showcases transformative blockbuster products for inflammatory","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/08/3270209/0/en/Mesoblast-R-D-Day-Features-Significant-Commercial-Progress-Platform-Innovation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BK4575","MSB","BK4150","LU2065732104.USD","PRGS","BK4006","MSC","MESO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625949485","title":"Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625949485","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625949485?lang=en_us&edition=fundamental","pubTime":"2026-04-08 16:35","pubTimestamp":1775637306,"startTime":"0","endTime":"0","summary":"Wondering if Mesoblast at around A$2.02 is giving you genuine value or just fresh volatility? This article walks through what the numbers are actually saying about the stock.\nThe share price has had a mixed run, with a 7 day return of an 11.0% decline and a 30 day return of a 4.3% decline, set against a year to date return of a 27.1% decline, a 1 year return of 25.9%, and a 3 year return of 112.0%.\nThese moves sit alongside ongoing attention on Mesoblast's position in the biotech sector and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-offering-value-after-recent-share-price","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-offering-value-after-recent-share-price","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","BK7508","BK7501","DCF","BK7067","BK4006","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625986886","title":"Macquarie Group Rise After Financing Mesabi's Minnesota Iron Ore Mine","url":"https://stock-news.laohu8.com/highlight/detail?id=2625986886","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625986886?lang=en_us&edition=fundamental","pubTime":"2026-04-07 10:24","pubTimestamp":1775528671,"startTime":"0","endTime":"0","summary":"Shares of Macquarie Group  rose around 3% in recent Tuesday trade after Mesabi Metallics said on Monday that it had secured $150 million in financing from the bank to support the third-quarter startup of its world-scale iron ore mine and pellet plant in Minnesota.The $2.5 billion project, spanning over 16,000 acres, aims to supply DR-grade iron ore for next-generation electric arc furnaces, representing one of Minnesota's largest private-sector industrial investments.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7511","BK7046","MQG.AU","BK4006","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625983628","title":"Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2625983628","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625983628?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:03","pubTimestamp":1775523780,"startTime":"0","endTime":"0","summary":"Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April  06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/07/3268787/0/en/Ryoncil-Continues-Successful-First-Year-Launch-with-Net-Sales-of-US-30-3M-in-March-Quarter.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","BK4139","MSB","MSC","BK4006","BK4575","MESO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mesabi-trust.com","stockEarnings":[{"period":"1week","weight":0.0036},{"period":"1month","weight":-0.1028},{"period":"3month","weight":-0.1548},{"period":"6month","weight":-0.2805},{"period":"1year","weight":0.0325},{"period":"ytd","weight":-0.3567}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States. Mesabi Trust was founded in 1961 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.565217,"avgChangeRate":0.059897},{"month":2,"riseRate":0.565217,"avgChangeRate":0.031389},{"month":3,"riseRate":0.413043,"avgChangeRate":0.011673},{"month":4,"riseRate":0.382979,"avgChangeRate":-0.006266},{"month":5,"riseRate":0.510638,"avgChangeRate":0.00885},{"month":6,"riseRate":0.361702,"avgChangeRate":-0.010466},{"month":7,"riseRate":0.347826,"avgChangeRate":-0.009187},{"month":8,"riseRate":0.413043,"avgChangeRate":0.000339},{"month":9,"riseRate":0.413043,"avgChangeRate":0.003772},{"month":10,"riseRate":0.391304,"avgChangeRate":-0.005844},{"month":11,"riseRate":0.478261,"avgChangeRate":-0.001259},{"month":12,"riseRate":0.434783,"avgChangeRate":0.025908}],"exchange":"NYSE","name":"Mesabi","nameEN":"Mesabi"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mesabi(MSB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mesabi,MSB,Mesabi股票,Mesabi股票老虎,Mesabi股票老虎国际,Mesabi行情,Mesabi股票行情,Mesabi股价,Mesabi股市,Mesabi股票价格,Mesabi股票交易,Mesabi股票购买,Mesabi股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mesabi(MSB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction